Lung Cancer News

Healio spoke with Rebecca L. Siegel, MPH, senior scientific direct of surveillance research at the American Cancer Society, to learn more about earlier detection of lung cancer and how it has helped patients increase their odds of survival and helped clinicians effectively treat their patients.

Incidental respiratory disease-related findings, including emphysema and reticular opacities, observed on low-dose CT lung cancer screenings were common and associated with increased mortality, researchers reported.

Men, smokers and younger patients with non-small cell lung cancer all appeared to derive more benefit from immunotherapy, according to a systematic review published in JNCI Cancer Spectrum.

The FDA granted priority review to trastuzumab deruxtecan for treatment of adults with unresectable or metastatic HER2-mutated non-small cell lung cancer, according to a press release from the agent’s manufacturer.

Patients with non-small cell lung cancer exhibited less depression and anxiety when receiving treatment during the COVID-19 pandemic than healthy individuals, according to a study in Journal of National Comprehensive Cancer Network.

The FDA granted orphan drug designation to serplulimab for treatment of small cell lung cancer.

Neoadjuvant nivolumab plus chemotherapy significantly improved EFS in stage IB to stage IIIA resectable non-small cell lung cancer, according to research presented at American Association for Cancer Research Annual Meeting.

Patients with non-small cell lung cancer and an exceptionally high anti-PD-1 therapy response more frequently had a variant of the CTLA-4 gene, which may be used to identify those who may benefit from such treatment.

Sotorasib exhibited durable efficacy among certain adults with locally advanced or metastatic non-small cell lung cancer, according to study results presented at American Association for Cancer Research Annual Meeting.

Although smoking cessation is known to benefit patients with cancer, obstacles exist at the patient, clinician and institutional levels, according to a poster presentation at American Association for Cancer Research Annual Meeting.